Cardiff Oncology, Inc.
CRDF
$1.05
-$0.05-4.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 153.66% | -83.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 153.66% | -83.13% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 153.66% | 100.85% | |||
| SG&A Expenses | -37.90% | 104.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.61% | 59.74% | |||
| Operating Income | 25.18% | -64.18% | |||
| Income Before Tax | 25.22% | -71.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.22% | -71.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.22% | -71.08% | |||
| EBIT | 25.18% | -64.18% | |||
| EBITDA | 25.35% | -64.92% | |||
| EPS Basic | 25.24% | -68.72% | |||
| Normalized Basic EPS | 25.24% | -68.76% | |||
| EPS Diluted | 25.24% | -68.72% | |||
| Normalized Diluted EPS | 25.24% | -68.76% | |||
| Average Basic Shares Outstanding | 0.07% | 1.36% | |||
| Average Diluted Shares Outstanding | 0.07% | 1.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||